IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Journal of Clinical Investigation

Volumn 127, Issue 8, 2017, Pages 2930-2940

  Ayers, Mark ^a   Lunceford, Jared ^a   Nebozhyn, Michael ^a   Murphy, Erin ^a   Loboda, Andrey ^a   Kaufman, David R ^a   Albright, Andrew ^a   Cheng, Jonathan D ^a   Kang, S Peter ^a   Shankaran, Veena ^b   Piha Paul, Sarina A ^c   Yearley, Jennifer ^a   Seiwert, Tanguy Y ^d   Ribas, Antoni ^e   McClanahan, Terrill K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; MESSENGER RNA; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; STAT1 PROTEIN; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; IFNG PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN PRESENTATION; ARTICLE; BLADDER CANCER; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; GENE EXPRESSION PROFILING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; LUNG NEOPLASMS; MELANOMA; PILOT PROJECTS; PROGRAMMED CELL DEATH 1 RECEPTOR; ROC CURVE; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85026675148     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI91190     Document Type: Article

References (30)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
3. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
4. Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
5. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245.
6. Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
7. Zaidi MR, et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature. 2011;469(7331):548-553.
8. Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
9. Faridi R, Zahra A, Khan K, Idrees M. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J. 2011;8:269.
10. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95-109.
11. Bald T, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4(6):674-687.
12. Liang SC, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33(10):2706-2716.
13. Abiko K, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501-1509.
14. Bellucci R, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824.
15. Spranger S, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.
16. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
17. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
18. Wallden B, et al. Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System. J Clin Oncol. 2016;34(15 suppl):3034.
19. Seiwert TY, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an openlabel, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-965.
20. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
21. + T-cell recruitment. Cancer Res. 2009;69(7):3077-3085.
22. Taube JM, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
23. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61.
24. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915-919.
25. Spranger S, Bao R, Gajewski TF. Melanomaintrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231-235.
26. Feig C, et al. Targeting CXCL12 from FAPexpressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212-20217.
27. Motz GT, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607-615.
28. Keytruda (pembrolizumab) for injection, for intravenous use [package insert]. Kenilworth, New Jersey, USA: Merck Sharp & Dohme Corp.; 2017.
29. Dako, an Agilent Technologies company, announces FDA approval of new companion diagnostic for lung cancer [press release]. Carpinteria, California, USA(5): Agilent Technologies; October 5, 2015.
30. Zou H, Hastie T. Regularization and variable selection via the elastic net. J Royal Statist Soc B. 2005;67(part 2):301-320.